Jay S. Duker

Nov 27, 2024 | healio.com | Jay S. Duker |Anthony DeFino |Christine Klimanskis

You've successfully added Retina/Vitreous in Ophthalmology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — In this Healio Video Perspective from the AAO meeting, Jay S.

May 9, 2024 | healio.com | Jay S. Duker |Anthony DeFino |Christine Klimanskis

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Jay S. Duker, MD,of EyePoint Pharmaceuticals discusses lead product Duravyu.

May 7, 2024 | healio.com | Eamon Dreisbach |Anthony DeFino |Christine Klimanskis |Jay S. Duker

Read more You've successfully added Retina/Vitreous in Ophthalmology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The trial did not reach a two-step or greater improvement in DRSS at 36 months after Duravyu injection.

Jan 13, 2024 | healio.com | Jay S. Duker |David Mullin |Eamon Dreisbach

WAILEA, Hawaii — In this Healio video perspective from Hawaiian Eye/Retina 2024, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, discusses the phase 2 DAVIO 2 results for EYP-1901 for the treatment of wet AMD. “The DAVIO 2 trial consisted of 160 patients randomly assigned to either 2 mg of EYP-1901 or 3 mg of EYP-1901 vs. an on-label aflibercept control,” Duker said.

Jul 21, 2023 | healio.com | Daniel Azzam |Jay S. Duker |Christine Klimanskis

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A 58-year-old white woman was referred to the retina service at the New England Eye Center for a new right eye choroidal mass. She endorsed right eye progressive vision decline with nasal field defect and flashes for 6 months, as well as redness and pain for 2 days.